Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Serving US Federal and NGO clients.
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic
areas. Managing studies in all major geographies, we have
established solid working relationships with the world’s
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
Offering solutions that combine in-house expertise and proprietary innovative technology.
We develop integrated technologies to significantly enhance
the efficiency and productivity of clients’ drug and device
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Digital solutions that increase efficiency in clinical trials by driving site performance.
BioPharma companies and Medical Devices manufacturers face
growing operational, regulatory and economic challenges. ICON
provides analysis and key insights on these challenges, with
practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
The cost pressures on drug development are driving the search for savings. Results from an industry survey by ICON and Pharma Intelligence.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
ICON experts frequently author or contribute to industry trade press. Read some recent articles.
Browse for topics across the drug development lifecycle
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.